LMP744 (MJ-III65)
(Synonyms: MJ-III65; NSC706744) 目录号 : GC33389LMP744 (MJ-III65) (MJ-III65) 是一种 DNA 嵌入剂和拓扑异构酶 I (Top1) 抑制剂,具有抗肿瘤活性。
Cas No.:308246-52-8
Sample solution is provided at 25 µL, 10mM.
LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase (Top1) inhibitor with antitumor activity[1].
The GI50 value of LMP744 (MJ-III-65) for NCI60 cells is 0.1 μM[1].LMP744 (0.1-5 μM, 3 days) induces dose-dependent accumulation of cells in the S and G2 phases of the cell cycle[1].|| Cell Viability Assay[1]||Cell Line:|P388 and P388 Top1-deficient murine leukemia cells|Concentration:|0.1-100 μM|Incubation Time:|3 days|Result:|induced dose-dependent accumulation of cells in the S and G2 phases of the cell cycle
MJ-III-65 (10-50 mg/kg) administered i.v. push once a week for 4 weeks in nude mice moderately actives against human A253 and FaDu tumor xenografts without significant toxicity[2].|| Animal Model:|Athymic nude mice (nu/nu, female, 20-25 g, 8-12 weeks old) transplanted with A253 and FaDu human head and neck xenografts[2].|Dosage:|10, 25, or 50 mg/kg/week, 4 weeks|Administration:|i.v. push via tail vein|Result:|moderately actived against human A253 and FaDu tumor xenografts without significant toxicity
[1]. Antony S, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res. 2007 Nov 1;67(21):10397-405. [2]. Antony S, et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Pharmacol. 2005 Feb;67(2):523-30.
Cas No. | 308246-52-8 | SDF | |
别名 | MJ-III65; NSC706744 | ||
Canonical SMILES | OCCNCCCN1C2=C(C(C3=CC(OCO4)=C4C=C23)=O)C5=CC(OC)=C(OC)C=C5C1=O | ||
分子式 | C24H24N2O7 | 分子量 | 452.46 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2101 mL | 11.0507 mL | 22.1014 mL |
5 mM | 0.442 mL | 2.2101 mL | 4.4203 mL |
10 mM | 0.221 mL | 1.1051 mL | 2.2101 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet